perindopril has been researched along with Diabetic Cardiomyopathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Gao, F; Hao, P; Liu, Y; Yang, J; Zhang, C; Zhang, K; Zhang, M; Zhang, Y | 1 |
| Kanorskaia, IuS; Kanorskiĭ, SG | 1 |
2 other study(ies) available for perindopril and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Combination of angiotensin-(1-7) with perindopril is better than single therapy in ameliorating diabetic cardiomyopathy.
Topics: Angiotensin I; Angiotensin-Converting Enzyme 2; Animals; Apoptosis; Blood Glucose; Cardiomegaly; Cell Communication; Cell Differentiation; Cell Proliferation; Collagen; Diabetic Cardiomyopathies; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Fibroblasts; Fibrosis; Heart Ventricles; Hemodynamics; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Peptide Fragments; Peptidyl-Dipeptidase A; Perindopril; Phosphorylation; Rats; Receptors, Angiotensin; Transforming Growth Factor beta1; Ventricular Dysfunction, Left | 2015 |
[Atrial fibrillation in patients with type 2 diabetes mellitus: specific features of development and antirecurrence therapy].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Atrial Fibrillation; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diabetic Neuropathies; Drug Monitoring; Female; Heart Conduction System; Heart Failure, Diastolic; Humans; Male; Middle Aged; Perindopril; Random Allocation; Secondary Prevention; Sotalol; Thioctic Acid; Treatment Outcome; Ventricular Dysfunction, Left | 2010 |